Status:
UNKNOWN
Usefulness of the Artery First Approach in Pancreatic Cancer Surgery
Lead Sponsor:
Asan Medical Center
Conditions:
Pancreatic Cancer, Adult
Margin, Tumor-Free
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
This study is aimed to evaluate difference of the 2 year recurrence free survival after pancreaticoduodenectomy for pancreatic cancer between artery-first approach and conventional procedure groups.
Detailed Description
The patients will be divided into 2 groups conventional group: The patients who included this group will undergo conventional pancreaticoduodenectomy (PD) or pylorus preserving pancreaticoduodenectom...
Eligibility Criteria
Inclusion
- Resectable pancreatic head cancer
- No systemic metastasis
- Age \> 20 years
- The patients who understand informed consent and is able to agree with study
Exclusion
- The patients who have systemic metastasis
- The patients who need neoadjuvant therapy in borderline resectable and locally advanced pancreatic cancer
- Those with active or uncontrolled infections
- Those with severe psychiatric / neurological disorders
- Alcohol or other drug addicts
- Patients with moderate or severe comorbidities who are thought to have an impact on quality of life or nutritional status (cirrhosis, chronic kidney failure, heart failure, etc.)
Key Trial Info
Start Date :
January 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
268 Patients enrolled
Trial Details
Trial ID
NCT04136522
Start Date
January 10 2020
End Date
December 31 2023
Last Update
July 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan medical center
Seoul, South Korea, 05505